
Opinion|Videos|December 5, 2025
Selectivity of TYK2 Inhibition in Psoriasis
Next-generation TIC-2 inhibitors show remarkable selectivity, enhancing efficacy while minimizing side effects, offering insights into immune system safety.
Advertisement
Episodes in this series

Panelists discuss the questions below in this video.
How does the selectivity of TYK2 inhibition differ from JAK inhibition?
At what level of pathway inhibition (% inhibition of IL-12, IL-23, IFN) do we see efficacy without safety liabilities, and how narrow or wide is this therapeutic window compared to JAK inhibitors?
Loss-of-function TYK2 variants have been linked to protection from psoriasis. How do these genetic findings inform our understanding of TYK2’s role and support selective inhibition as a therapeutic strategy?
Advertisement
Related to this article

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
One COPD Exacerbation Is Too Many: Vickram Tejwani, MD
4
Monthly PVX108 Raises Peanut Tolerance in Children, With Brian Vickery, MD
5

